We invite you to attend an upcoming public meeting on female sexual dysfunction, as part of FDA’s Patient-Focused Drug Development initiative. The goal of the meeting is to hear patient perspectives on symptoms of female sexual dysfunction that matter most to them and on current approaches to treating female sexual dysfunction. In order to focus on the patient’s voice, we ask that academia, industry, and others be in listening mode at the meeting.
Date: Monday, October 27, 2014
Time: 12:00 pm – 5:00 pm
Location: FDA White Oak campus at 10903 New Hampshire Avenue, Silver Spring, MD
In addition to the public meeting, you may be interested in a scientific workshop on female sexual dysfunction taking place on October 28, 2014 at the FDA White Oak campus. For more information on these two meetings, visit the FDA website: http://www.fda.gov/Drugs/NewsEvents/ucm401167.htm
Attendees for both meetings can register here: https://patient-focused-female-sexual-dysfunction.eventbrite.com. Remote access will be available via live webcast for those unable to attend in person. Please note that registration for in-person attendance and the webcast closes onOctober 20, 2014. A public docket will also be available, which will give patients an opportunity to submit comments to FDA online or through the mail up to 60 days after the meeting is held.
We’ve also developed a series of background webinars on FDA and Patient-Focused Drug Development. Watching these webinars in advance may be helpful in preparing for the meeting.
The patient voice is integral to FDA’s Patient-Focused Drug Development initiative. We encourage you to reach out to your peers, patients, and other patient stakeholders to spread the word by forwarding on this email and sharing through social media.